Evidence map›Paper›PMID 26907931›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2016

Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose.

Wentao Luo, Liumei Hu, Weiye Li, Guotong Xu, Linxinyu Xu, Conghui Zhang, Fang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Diabetic fibrosis.Biochimica et biophysica acta. Molecular basis of disease · 2021
    Review
  7. Article
  8. Article
  9. A Review of Last Decade Developments on Epiretinal Membrane Pathogenesis.Medical hypothesis, discovery & innovation ophthalmology journal · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Wentao LuoDepartment of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Liumei HuDepartment of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Weiye LiDepartment of Ophthalmology, Drexel University College of Medicine, Philadelphia, PA, USA.
Guotong XuDepartment of Ophthalmology of Shanghai Tenth People's Hospital and Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China.
Linxinyu XuDepartment of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Conghui ZhangDepartment of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Fang WangDepartment of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. wangfangopth@163.com.
Tongji University · CNDrexel University · USShanghai Tenth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn proliferative diabetic retinopathy (PDR), Müller glial cells (MGCs) acquire migratory ability and exhibit a fibroblast-like phenotype. These activated MGCs contribute to the formation of epiretinal membrane, which will stretch the retina, and cause retinal detachment and vitreous hemorrhage. Erythropoietin (Epo) is now found effective in ameliorating renal fibrosis by inhibiting epithelial-to-mesenchymal transition of tubular epithelial cells. This study is undertaken to determine whether Epo has an effect in inhibiting MGCs activation to attenuate epiretinal membrane formation in PDR.

methodMIO-M1 cell line was used in this study. As a pilot test to determine the most efficient treatment time and concentration of Epo, levels of connective tissue growth factor (CTGF) and transforming growth factor-β (TGF-β) were measured by real-time PCR, after treatment with Epo on MGCs cultured in high glucose. MGCs were cultured in high glucose and normal glucose for 2 days, with or without TGF-β as a pro-fibrogenic cytokine. Epo was introduced at the same time. Immunofluorescence targeting α-smooth muscle actin (α-SMA), fibronectin, and glial fibrillary acidic protein (GFAP) was performed to explore the cell phenotype. Matrix metalloproteinase 9 (MMP9) mRNA level was detected by real-time PCR. Protein levels of CTGF and cytoskeletal proteins like α-SMA and fibronectin were measured by enzyme-linked immunosorbent assay (ELISA) and Western blot respectively. Wound-healing assay was applied to evaluate the migratory ability of MGCs, and actin-tracker green was used to draw the structure of F-actin in MGCs.

resultsAfter being seeded into high-glucose medium containing TGF-β, MGCs expressed a larger amount of MMP9 mRNA as well as α-SMA, fibronectin at protein level. They secreted more CTGF, and their F-actin reorganized in a parallel manner and showed a stronger ability to migrate. In addition, these changes, including mRNA and protein expression, F-actin assembling, and cell migration, could be attenuated significantly by Epo treatment.

conclusionHigh glucose together with TGF-β promote MGCs to exhibit a fibroblast-like phenotype and develop a greater migratory ability. These changes can be inhibited by Epo, which therefore may contribute to the controlling of epiretinal membrane formation.

Indexed as

ActinsBlotting, WesternCell LineCell MovementConnective Tissue Growth FactorEnzyme-Linked Immunosorbent AssayEpendymoglial CellsErythropoietinFibronectinsFibrosisFluorescent Antibody Technique, IndirectGlial Fibrillary Acidic ProteinGlucoseHumansMatrix Metalloproteinase 9Real-Time Polymerase Chain ReactionACTA2 protein, humanActinsCCN2 protein, humanConnective Tissue Growth FactorErythropoietinFibronectinsGlial Fibrillary Acidic ProteinGlucoseMatrix Metalloproteinase 9MMP9 protein, humanRNA, MessengerTransforming Growth Factor betaEpiretinal membrane formationErythropoietinMüller glial cellsPhenotypeProliferative Diabetic Retinopathy

Identifiers

PMID26907931
OpenAlexW2287705594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.